XTL Biopharmaceuticals Ltd. (XTLB)
NASDAQ: XTLB · Real-Time Price · USD
1.960
+0.050 (2.62%)
Oct 16, 2026, 4:00 PM EDT - Market closed
XTL Biopharmaceuticals Market Cap
XTL Biopharmaceuticals has a market cap or net worth of $6.1 million as of October 16, 2026. Its market cap has decreased by 52.57% in one year.
Market Cap
6.10M
Enterprise Value
6.03M
1-Year Change
-52.57%
Global Rank
n/a
Country Rank
n/a
Category
ChartMarket Cap Chart
Since September 1, 2005, XTL Biopharmaceuticals's market cap has decreased from $190.39M to $6.10M, a decrease of -96.79%. That is a compound annual growth rate of -15.02%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 15, 2026 | 6.40M | -10.13% |
| Dec 31, 2025 | 7.12M | -68.18% |
| Dec 31, 2024 | 22.38M | 322.69% |
| Dec 31, 2023 | 5.30M | -16.54% |
| Dec 29, 2022 | 6.35M | -57.67% |
| Dec 30, 2021 | 14.99M | -4.38% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Exicure | 7.53M |
| CollPlant Biotechnologies | 7.39M |
| Soligenix | 7.29M |
| Longeveron | 6.85M |
| Skye Bioscience | 6.77M |
| FibroBiologics | 6.68M |
| Alzamend Neuro | 6.51M |
| NeuroSense Therapeutics | 6.45M |